Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

BACKGROUND: Bevacizumab and temsirolimus are active agents in advanced solid tumors. Temsirolimus inhibits mTOR in the PI3 kinase/AKT/mTOR pathway as well as CYP2A, which may be a resistance mechanism for cetuximab. In addition, temsirolimus attenuates upregulation of HIF-1α levels, which may be a r...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2016
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029622/
https://ncbi.nlm.nih.gov/pubmed/26933802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7594
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料